Q/C Technologies, Inc. Proceeds from Contributed Capital
Q/C Technologies, Inc. (QCLS) reported Proceeds from Contributed Capital of $14.50 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromContributedCapital · last filed 2021-03-01
- Q/C Technologies, Inc. proceeds from contributed capital for the quarter ending 2020-12-31 was $600.00.
- Q/C Technologies, Inc. proceeds from contributed capital for the quarter ending 2020-09-30 was $15.38K, a 230.80% increase year-over-year.
- Q/C Technologies, Inc. proceeds from contributed capital for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Q/C Technologies, Inc. proceeds from contributed capital for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Q/C Technologies, Inc. proceeds from contributed capital for fiscal 2020 was $14.50K, a 62.71% decline from fiscal 2019.
- Q/C Technologies, Inc. proceeds from contributed capital for fiscal 2019 was $38.89K.
| Period end | Proceeds from Contributed Capital 3 month | Proceeds from Contributed Capital 6 month | Proceeds from Contributed Capital 9 month | Proceeds from Contributed Capital 12 month |
|---|---|---|---|---|
| 2020-12-31 | $600.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $15.98K derived: sum of 2 quarters · filed 2021-03-01 | $15.98K derived: sum of 3 quarters · filed 2021-03-01 | $14.50K 10-K · filed 2021-03-01 |
| 2020-09-30 | $15.38K 10-Q · filed 2020-11-16 | $15.38K derived: sum of 2 quarters · filed 2020-11-16 | $13.90K 10-Q · filed 2020-11-16 | $15.38K derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 | $9.25K 10-Q · filed 2020-08-14 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $4.65K derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $4.65K derived: sum of 3 quarters · filed 2021-03-01 | $13.90K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.65K derived: sum of 2 quarters · filed 2021-03-01 | $13.90K derived: sum of 3 quarters · filed 2021-03-01 | $38.89K 10-K · filed 2021-03-01 |
| 2019-09-30 | $4.65K 10-Q · filed 2020-11-16 | $13.90K derived: sum of 2 quarters · filed 2020-11-16 | $38.89K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $9.25K 10-Q · filed 2020-08-14 | $23.51K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $23.51K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |